These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2632058)

  • 1. Endogenous and exogenous testosterone levels after administration of deuterium-labelled testosterone propionate in hypogonadotropic hypogonadism.
    Fujioka M; Shinohara Y; Baba S; Irie M; Inoue K
    Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):3100-1. PubMed ID: 2632058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic studies of testosterone propionate using gas chromatography/mass spectrometry/selected ion monitoring.
    Shinohara Y; Fujioka M; Baba S
    Biomed Environ Mass Spectrom; 1988 Oct; 16(1-12):241-4. PubMed ID: 3242676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of testosterone propionate in normal men.
    Fujioka M; Shinohara Y; Baba S; Irie M; Inoue K
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1361-4. PubMed ID: 3782423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of testosterone propionate in human plasma by gas chromatography-mass spectrometry.
    Baba S; Fujioka M; Shinohara Y; Furuta T
    J Chromatogr; 1985 Feb; 337(2):205-12. PubMed ID: 3988852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone treatment of hypogonadal men participating in competitive sports.
    Gooren LJ; Behre HM
    Andrologia; 2008 Jun; 40(3):195-9. PubMed ID: 18477208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
    Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpectedly prolonged washout period of exogenous testosterone after discontinuation of intramuscular testosterone undecanoate depot injection (Nebido(®) or Reandron(®) ) in men with congenital hypogonadotrophic hypogonadism.
    Gan EH; Bouloux PM; Quinton R
    Clin Endocrinol (Oxf); 2016 Jun; 84(6):947-50. PubMed ID: 26732131
    [No Abstract]   [Full Text] [Related]  

  • 8. Differentiation between endogenous and exogenous testosterone in human plasma and urine after oral administration of deuterium-labeled testosterone by mass fragmentography.
    Baba S; Shinohara Y; Kasuya Y
    J Clin Endocrinol Metab; 1980 May; 50(5):889-94. PubMed ID: 7189522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of male hypogonadotropic hypogonadism by pulsatile administration of gonadotropin-releasing hormones].
    von Werder K; Eversmann T
    Dtsch Med Wochenschr; 1984 Mar; 109(11):432-4. PubMed ID: 6365500
    [No Abstract]   [Full Text] [Related]  

  • 10. Metoclopramide-mediated prolactin secretion in patients with idiopathic hypogonadotropic hypogonadism: effect of testosterone therapy.
    Modebe O
    Fertil Steril; 1989 May; 51(5):855-8. PubMed ID: 2707462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men.
    Raynaud JP; Aumonier C; Gualano V; Betea D; Beckers A
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):177-84. PubMed ID: 18325758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of idiopathic hypogonadotropic hypogonadism.
    Raivio T; Falardeau J; Dwyer A; Quinton R; Hayes FJ; Hughes VA; Cole LW; Pearce SH; Lee H; Boepple P; Crowley WF; Pitteloud N
    N Engl J Med; 2007 Aug; 357(9):863-73. PubMed ID: 17761590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of sex steroids in patients with beta thalassaemia major.
    Katz M; De Sanctis V; Vullo C; Wonke B; McGarrigle HH; Bagni B
    J Clin Pathol; 1993 Jul; 46(7):660-4. PubMed ID: 8157756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary hypogonadism in men by the transdermal administration of testosterone.
    Findlay JC; Place V; Snyder PJ
    J Clin Endocrinol Metab; 1989 Feb; 68(2):369-73. PubMed ID: 2493029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients.
    Cakir E; Ozcan O; Yaman H; Akgul EO; Bilgi C; Erbil MK; Yesilova Z
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1651-4. PubMed ID: 15613405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.